Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

AKM Claessens; FLG Erdkamp; M Lopez-Yurda; JM Bouma; JM Rademaker-Lakhai; AH Honkoop; H de Graaf; VC Tjan-Heijnen; Monique Bos

doi:10.1080/0284186X.2020.1731923

Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

AKM Claessens
, FLG Erdkamp
, M Lopez-Yurda
, JM Bouma
, JM Rademaker-Lakhai
, AH Honkoop
, H de Graaf
, VC Tjan-Heijnen
, Monique Bos

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

78 Downloads (Pure)

Original language	English
Pages (from-to)	713-722
Number of pages	10
Journal	Acta Oncologica
Volume	59
Issue number	6
DOIs	https://doi.org/10.1080/0284186X.2020.1731923
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC OR-01

Access to Document

10.1080/0284186X.2020.1731923

RePub-125472.pdfFinal published version, 1.4 MB

Cite this

Claessens, AKM., Erdkamp, FLG., Lopez-Yurda, M., Bouma, JM., Rademaker-Lakhai, JM., Honkoop, AH., de Graaf, H., Tjan-Heijnen, VC., & Bos, M. (2020). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncologica, 59(6), 713-722. https://doi.org/10.1080/0284186X.2020.1731923

@article{4999cf0a42b34873a80a1840106c0e50,

title = "Secondary analyses of the randomized phase III Stop\&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer",

author = "AKM Claessens and FLG Erdkamp and M Lopez-Yurda and JM Bouma and JM Rademaker-Lakhai and AH Honkoop and \{de Graaf\}, H and VC Tjan-Heijnen and Monique Bos",

year = "2020",

doi = "10.1080/0284186X.2020.1731923",

language = "English",

volume = "59",

pages = "713--722",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "6",

}

Claessens, AKM, Erdkamp, FLG, Lopez-Yurda, M, Bouma, JM, Rademaker-Lakhai, JM, Honkoop, AH, de Graaf, H, Tjan-Heijnen, VC & Bos, M 2020, 'Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer', Acta Oncologica, vol. 59, no. 6, pp. 713-722. https://doi.org/10.1080/0284186X.2020.1731923

TY - JOUR

T1 - Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

AU - Claessens, AKM

AU - Erdkamp, FLG

AU - Lopez-Yurda, M

AU - Bouma, JM

AU - Rademaker-Lakhai, JM

AU - Honkoop, AH

AU - de Graaf, H

AU - Tjan-Heijnen, VC

AU - Bos, Monique

PY - 2020

Y1 - 2020

U2 - 10.1080/0284186X.2020.1731923

DO - 10.1080/0284186X.2020.1731923

M3 - Article

C2 - 32141389

SN - 0284-186X

VL - 59

SP - 713

EP - 722

JO - Acta Oncologica

JF - Acta Oncologica

IS - 6

ER -